Pfizer plans 20 pivotal studies and four regulatory decision
布尔拉表示，公司计划今年启动20项关键性研究，并预计有四项监管决定，称2026年是“研发的关键之年”。
English original
Bourla said the company is planning to begin 20 pivotal studies this year and anticipates four regulatory decisions, calling 2026 "a pivotal year for R&D."
在辉瑞第一季度财报电话会议上
报道摘要
On Pfizer's first-quarter earnings call, CEO Albert Bourla was optimistic that in 2029, the company will begin a five-year period of strong growth, with revenue growth rates in the high single digits.
The Motley Fool